Tim Fagan's Law
Latest action · Dec 11, 2014 Referred to the House Committee on Energy and Commerce.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedDec 11, 2014
- Passed HouseNot reached
- Passed SenateNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Tim Fagan's Law or Counterfeit Drug Enforcement Act of 2014 - Amends the Federal Food, Drug, and Cosmetic Act (FFDCA) to establish a criminal fine and/or imprisonment for a person who: (1) knowingly causes a prescription drug to be adulterated, misbranded, or misrepresented as an approved prescription drug and sells or trades the drug; or (2) purchases or trades for a drug knowing or having reason to know that the drug was knowingly adulterated, misbranded, or misrepresented. Requires a manufacturer of a drug to notify the Department of Health and Human Services (HHS) within 48 hours after first receiving or becoming aware of information that reasonably suggests that such a violation may have occurred.
Deems a drug to be misbranded if it is not manufactured using technologies that HHS determines are technically feasible and assist in preventing such violations.
Authorizes additional appropriations for Food and Drug Administration (FDA) inspections, examinations, and investigations.
Requires HHS to educate the public and health care professionals on counterfeit drugs.
Directs HHS, upon a finding that a drug intended for human use may constitute a threat to the public health, to issue an order requiring the appropriate person (including the manufacturers, importers, distributors, or retailers of the drug) to cease distribution of the drug and to notify and instruct health professionals to cease administering, distributing, selling, or prescribing the drug. Requires HHS, after providing the person with an opportunity for an informal hearing, to amend the order to include a recall, if appropriate.
Requires HHS and the Attorney General to establish a procedure through which the FDA is authorized to issue subpoenas.
Cosponsors
Members who signed on, in the order they did.
Actions 2
Everything that happened, newest first.
- Dec 11, 2014Introduced in House
- Dec 11, 2014Referred to the House Committee on Energy and Commerce.
Subjects
Assigned by the Library of Congress. Policy area: Health.
- Administrative law and regulatory procedures
- Administrative remedies
- Criminal investigation, prosecution, interrogation
- Criminal justice information and records
- Department of Health and Human Services
- Department of Justice
- Drug safety, medical device, and laboratory regulation
- Food and Drug Administration (FDA)
- Fraud offenses and financial crimes
- Government information and archives
- Government studies and investigations
- Health
- Health information and medical records
- Health programs administration and funding
- Manufacturing
- Marketing and advertising
- Prescription drugs
- Retail and wholesale trades
Text 1
Each version as it was printed, newest first.
- Dec 11, 2014Introduced in House
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov.